No Result

View All Result

No products in the cart.

Home Tag bortezomib

Tag: bortezomib

#VisualAbstract: Daratumumab-based therapies were associated with higher rates of sustained minimal residual disease negativity in patients with newly diagnosed multiple myeloma

byKathleen Lau

February 3, 2022

#VisualAbstract An ixazomib-based regimen may be a better-tolerated approach in elderly patients with newly diagnosed multiple myeloma

byKathleen Lau

December 18, 2021

#VisualAbstract Addition of daratumumab to standard of care improves minimal residual disease negativity in patients with newly diagnosed, transplant-ineligible multiple myeloma

byKathleen Lau

July 23, 2021

Amyloidogenic genetic variant not associated with increased mortality in blacks

Daratumumab therapy addition improved response in systemic immunoglobulin light-chain amyloidosis

bySze Wah Samuel Chanand1 others

July 14, 2021

1. Daratumumab therapy addition to bortezomib, cyclophosphamide, and dexamethasone showed improved cancer response in patients with systemic immunoglobulin light-chain amyloidosis. ...

$#VisualAbstract CASTOR trial follow-up: Health-related quality of life was maintained in patients treated with daratumumab, bortezomib, and dexamethasone over time for relapsed or refractory multiple myeloma$

#VisualAbstract CASTOR trial follow-up: Health-related quality of life was maintained in patients treated with daratumumab, bortezomib, and dexamethasone over time for relapsed or refractory multiple myeloma

byKathleen Lau

March 4, 2021

$#VisualAbstract Panobinostat, lenalidomide, bortezomib, and dexamethasone was well-tolerated and showed potential in treating relapsed/refractory multiple myeloma$

#VisualAbstract Panobinostat, lenalidomide, bortezomib, and dexamethasone was well-tolerated and showed potential in treating relapsed/refractory multiple myeloma

byKathleen Lau

February 25, 2021

#VisualAbstract Bortezomib, cyclophosphamide, and dexamethasone demonstrated a modest median event-free survival in transplant ineligible patients with multiple myeloma

byKathleen Lau

February 18, 2021

$Phase II O-12-M1: Melflufen plus dexamethasone showed benefits in long-term survival outcomes in relapsed/refractory multiple myeloma$

Phase II O-12-M1: Melflufen plus dexamethasone showed benefits in long-term survival outcomes in relapsed/refractory multiple myeloma

byKathleen Lau

February 5, 2021

#VisualAbstract Lenalidomide shows improvement in progression-free survival over bortezomib maintenance following autologous stem cell transplantation for multiple myeloma

byKathleen Lau

January 28, 2021

#VisualAbstract SWOG-1211: Addition of elotuzumab to RVd induction and maintenance (lenalidomide, bortezomib, dexamethasone) did not improve patient outcomes in untreated, high-risk multiple myeloma

byKathleen Lau

January 14, 2021

Page 1 of 2 1 2 Next

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

No Result

View All Result